Title
Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants
Conference Dates
June 17-22, 2018
Abstract
Archaeosomes are liposomes comprised of ether lipids derived from various archaea which, as adjuvants, can induce robust, long-lasting humoral and cell-mediated immune responses to entrapped antigens. Traditional total polar lipid (TPL) archaeosome formulations are relatively complex and semi-synthetic archaeosomes involve many synthetic steps to arrive at the final desired glycolipid composition. We have developed a novel archaeosome formulation comprising a sulfated saccharide group covalently linked to the free sn-1 hydroxyl backbone of an archaeal core lipid (sulfated S-lactosylarchaeol, SLA) mixed with uncharged glycolipid (lactosylarchaeol, LA). This new class of adjuvants can be easily synthesized and retains strong immunostimulatory activity for induction of cell-mediated immunity following systemic immunization. Herein, we demonstrate the safety of SLA/LA archaeosomes following intramuscular injection to mice and evaluate the immunogenicity, in vivo distribution and cellular uptake of antigen (ovalbumin) encapsulated into SLA/LA archaeosomes. Overall, we have found that semi-synthetic sulfated glycolipid archaeosomes are a safe and effective novel class of adjuvants capable of inducing strong antigen-specific immune responses in mice and protection against subsequent B16 melanoma tumor challenge. A key step in their mechanism of action appears to be the recruitment of immune cells to the injection site and the subsequent trafficking of antigen to local draining lymph nodes. A better understanding of the safety and mechanism of action of novel adjuvants such as archaeosomes is a key step in their advancement into clinical use.
Recommended Citation
Mike McCluskie, Felicity C. Stark, Yimei Jia, Umar Iqbal, Lise Deschatelets, Renu Dudani, Blair Harrison, Lakshmi Krishnan, and Michael J. McCluskie, "Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants" in "Vaccine Technology VII", Amine Kamen, McGill University Tarit Mukhopadhyay, University College London Nathalie Garcon, Bioaster Charles Lutsch, Sanofi Pasteur Eds, ECI Symposium Series, (2018). https://dc.engconfintl.org/vt_vii/114